Zentalis Pharmaceuticals, Inc.

Listed Company

ZNTLCIK 0001725160NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-137.06M

Total Assets

$288.97M

Equity

$216.20M

Shares Out

71.19M

Op. Cash Flow

$-125.25M

ZNTL$5.09+252.25% · past yearDBEQ Basic

Daily closing prices

Business

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, an investigational WEE1 inhibitor for ovarian cancer and other tumor types. The company is advancing azenosertib toward regulatory approval in Cyclin E1-positive platinum-resistant ovarian cancer, with Phase 2 and planned Phase 3 trials underway and Fast Track Designation from the FDA. Zentalis exclusively owns worldwide development and commercialization rights to azenosertib through in-licensing agreements and relies on third-party contract manufacturing organizations for drug production.

Summary from 10-K filed 2026-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues from Licensing and Sales of Intellectual Property	0	67	0	0	—
Research and development	107	168	190	173	176
Zentera in-process research and development	0	0	46	0	0
General and administrative	38	87	64	55	41
Restructuring	8	0	0	—	—
Goodwill impairment	0	4	0	0	—
Total operating expenses	153	259	300	227	217
Loss from operations	−153	−191	−300	−227	−217
Investment and other income, net	16	26	23	6	401,000
Net loss before income taxes	−137	−166	−277	−221	−165
Income tax expense (benefit)	442,000	177,000	−601,000	−469,000	−297,000
Loss on equity method investment	0	0	16	16	2
Net loss	−137	−166	−292	−237	−166
Net loss attributable to noncontrolling interests	0	−28,000	−114,000	−307,000	−7
Net loss attributable to Zentalis	−137	−166	−292	−237	−159
Net loss per common share outstanding, basic (in dollars per share)	−1.91	−2.33	−4.47	−4.48	−3.72
Net loss per common share outstanding, diluted (in dollars per share)	−1.91	−2.33	−4.47	−4.48	−3.72
Common shares used in computing net loss per share, basic (in shares)	72	71	65	53	43
Common shares used in computing net loss per share, diluted (in shares)	72	71	65	53	43

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	36	34	28	43	60
Marketable debt securities, available for sale	210	318	455	—	—
Marketable equity securities	0	19	0	—	—
Contracts receivable	0	5	0	—	4,000
Prepaid expenses and other current assets	7	10	14	15	11
Total current assets	253	386	497	452	351
Property and equipment, net	3	5	6	8	8
Operating lease right-of-use assets	26	33	36	42	45
Prepaid expenses and other assets	4	4	7	10	7
Restricted cash	3	3	3	3	3
Total assets	289	430	552	539	455
Accounts payable	7	7	15	11	12
Accrued expenses	29	45	54	45	32
Total current liabilities	37	53	69	57	44
Long-term lease liability	36	40	43	45	44
Other long-term liabilities	500,000	849,000	2	3	0
Total liabilities	73	93	114	105	90
Commitments and contingencies (see Note 10)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized; 69,085,980 and 71,282,400 shares issued and outstanding at December 31, 2025 and 2024, respectively	69,000	71,000	70,000	59,000	45,000
Additional paid-in capital	1,407	1,391	1,324	1,031	724
Accumulated other comprehensive income	196,000	558,000	2	−1	−125,000
Accumulated deficit	−1,191	−1,054	−889	−596	−360
Total stockholders' equity	216	337	437	434	—
Total liabilities and stockholders' equity	289	430	552	539	455

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	700,000	1	1	1	500,000
Operating lease right-of-use and fixed asset impairment	4	0	5	—	—
Noncash consideration portion of Zentera in-process research and development	0	0	15	0	0
Share-based compensation	21	67	55	47	36
(Gain)/loss on disposal of equipment	−660,000	−13,000	406,000	56,000	15,000
Non-cash impact of revenues from licensing and sales of intellectual property	0	−47	0	0	—
Non-cash recognized mark-to-market of equity securities	−1	−5	0	0	—
Accretion of discounts on marketable securities, net	−3	−8	−13	−4	908,000
Deferred income taxes	0	0	−853,000	−769,000	−48,000
Deconsolidation of Kalyra	0	−79,000	0	0	—
Accounts receivable	5	−5	0	0	413,000
Prepaid expenses and other assets	3	6	−6	−7	1
Accounts payable and accrued liabilities	−17	−18	11	16	14
Operating lease right-of-use assets and liabilities, net	201,000	264,000	623,000	4	1
Net cash used in operating activities	−125	−171	−208	−164	−154
Purchases of marketable debt securities	−139	−128	−549	−533	−364
Proceeds from maturities of marketable debt securities	250	271	505	422	366
Proceeds from sale of marketable equity securities	20	33	0	0	—
Proceeds from sale of property and equipment	698,000	65,000	0	0	—
Purchases of property and equipment	0	−221,000	−583,000	−3	−6
Net cash provided by (used in) investing activities	132	177	−44	−114	−18
Proceeds from issuance of common stock, net	5	0	236	258	172
Proceeds from issuance of common stock under equity incentive plans	304,000	349,000	2	3	8
Repurchase of common stock	−10	0	0	—	—
Net-settlement of restricted stock unit vesting	0	−241,000	0	0	−1
Net cash (used in) provided by financing activities	−4	108,000	237	261	179
Net increase (decrease) in cash, cash equivalents and restricted cash	2	6	−15	−17	6
Income taxes paid	85,000	359,000	140,000	12,000	20,000
Right-of-use assets obtained in exchange for operating lease liabilities	0	0	602,000	0	45

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Zentalis Pharmaceuticals, Inc.'s CIK number?

Zentalis Pharmaceuticals, Inc.'s SEC CIK number is 0001725160 (1725160). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Zentalis Pharmaceuticals, Inc.'s SEC filings?

All of Zentalis Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Zentalis Pharmaceuticals, Inc. last report earnings?

Zentalis Pharmaceuticals, Inc. (ZNTL) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001725160-26-000041). This is Zentalis Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Zentalis Pharmaceuticals, Inc.'s most recent earnings 8-K?

Zentalis Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001725160-26-000041. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Zentalis Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →